Claryx develops genomic surveillance technology—branded CloneLink—that reads genomes of confirmed patient infections, links related cases into outbreaks, and traces each to likely sources including environmental reservoirs. The platform also builds a digital twin of a hospital from air, water and surface sampling to locate reservoirs of transmission, and Claryx says its proprietary chemistry cuts the most expensive sequencing step by more than twentyfold so continuous running is affordable. The company was founded by Kurt and Dirk Hackenberger and is based in New York, and it is already live across multiple health systems. The team highlights peer-reviewed results from a two-year study at UPMC Presbyterian that found 172 otherwise undetected outbreaks, stopped 96% of traced outbreaks, and estimated avoided infections, deaths and a 3.2-fold return on the program cost. Claryx positions itself as building a "hospital immune system" that detects transmission in real time and confirms when interventions worked. The company announced a $3.5 million pre-seed raise to scale deployments and operations.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2026